Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy.

breast cancer chemotherapy discussion fertility preservation oncofertility

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 28 04 2021
accepted: 31 08 2021
entrez: 15 10 2021
pubmed: 16 10 2021
medline: 16 10 2021
Statut: epublish

Résumé

Female breast cancer (BC) patients exposed to gonadotoxic chemotherapy are at risk of future infertility. There is evidence of disparities in the discussion of fertility preservation for these patients. The aim of the study was to identify factors influencing the discussion of fertility preservation (FP). We analyzed consecutive BC patients treated by chemotherapy at Institut Curie from 2011-2017 and aged 18-43 years at BC diagnosis. The discussion of FP was classified in a binary manner (discussion/no discussion), based on mentions present in the patient's electronic health record (EHR) before the initiation of chemotherapy. The associations between FP discussion and the characteristics of patients/tumors and healthcare practitioners were investigated by logistic regression analysis. The median age of the 1357 patients included in the cohort was 38.7 years, and median tumor size was 30.3 mm. The distribution of BC subtypes was as follows: 702 luminal BCs (58%), 241 triple-negative breast cancers (TNBCs) (20%), 193 HER2 FP discussion rates are low and are influenced by patient and physician characteristics. There is therefore room for improvement in the promotion and systematization of FP discussion.

Identifiants

pubmed: 34650912
doi: 10.3389/fonc.2021.701620
pmc: PMC8507557
doi:

Types de publication

Journal Article

Langues

eng

Pagination

701620

Informations de copyright

Copyright © 2021 Hours, Toussaint, De Castelbajac, Sautter, Borghese, Frank, Coussy, Laas, Grandal, Dumas, Daoud, Guerin, Balezeau, Feron, Fourchotte, Kirova, Lerebours, Pierga, Guillot, Santulli, Grynberg, Sonigo, Reyrat, Soibinet-Oudot, Reyal and Hamy.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Fertil Steril. 2014 Mar;101(3):633-4
pubmed: 24559617
Breast. 2007 Dec;16 Suppl 2:S175-81
pubmed: 17804236
Ann Oncol. 2020 Apr;31(4):541-542
pubmed: 32085890
Hum Reprod Update. 2014 Sep-Oct;20(5):759-74
pubmed: 24833728
Hum Reprod. 1992 Nov;7(10):1342-6
pubmed: 1291557
Fertil Steril. 2011 May;95(6):1932-6
pubmed: 21371704
Bull Cancer. 2016 Nov;103(11):949-950
pubmed: 27816168
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
J Am Med Inform Assoc. 2014 Oct;21(e2):e332-40
pubmed: 24780721
JAMA Netw Open. 2020 Jul 1;3(7):e2010806
pubmed: 32678451
Fertil Steril. 2017 Jan;107(1):243-252.e5
pubmed: 27887709
J Gynecol Obstet Biol Reprod (Paris). 2013 May;42(3):246-51
pubmed: 23453919
JAMA Oncol. 2021 Jan 01;7(1):86-91
pubmed: 33211089
Cancer. 2012 Mar 15;118(6):1710-7
pubmed: 21887678
BMJ Open Qual. 2018 Aug 10;7(3):e000088
pubmed: 30167470
Arch Pathol Lab Med. 2014 Feb;138(2):241-56
pubmed: 24099077
J Clin Oncol. 2005 Feb 1;23(4):766-73
pubmed: 15681520
J Clin Oncol. 2018 Jul 1;36(19):1994-2001
pubmed: 29620997
Int Surg. 1996 Jan-Mar;81(1):57-60
pubmed: 8803708
JCO Clin Cancer Inform. 2019 Oct;3:1-12
pubmed: 31626565
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
Br J Cancer. 2013 Apr 30;108(8):1602-15
pubmed: 23579214
BMC Cancer. 2015 Aug 05;15:572
pubmed: 26239242
J Oncol Pract. 2010 Jul;6(4):195-7
pubmed: 21037871
JAMA Netw Open. 2019 Nov 1;2(11):e1914511
pubmed: 31693121
J Adolesc Young Adult Oncol. 2019 Apr;8(2):197-204
pubmed: 30676852
J Clin Oncol. 2005 Aug 1;23(22):5155-65
pubmed: 16051957
Fertil Steril. 2010 Oct;94(5):1652-6
pubmed: 19945099

Auteurs

Alice Hours (A)

Department of Surgery, Institut Curie, University Paris, Paris, France.

Aullene Toussaint (A)

Department of Surgery, Institut Curie, University Paris, Paris, France.
Department of Medical Oncology, Institut Curie, University Paris, Paris, France.
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Victoire De Castelbajac (V)

Department of Medical Oncology, Institut Curie, University Paris, Paris, France.
Sénopole Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, University Paris, Paris, France.

Camille Sautter (C)

Department of Surgery, Institut Curie, University Paris, Paris, France.

Julie Borghese (J)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Sophie Frank (S)

Department of Medical Oncology, Institut Curie, University Paris, Paris, France.

Florence Coussy (F)

Department of Medical Oncology, Institut Curie, University Paris, Paris, France.

Enora Laas (E)

Department of Surgery, Institut Curie, University Paris, Paris, France.
Department of Medical Oncology, Institut Curie, University Paris, Paris, France.

Beatriz Grandal (B)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Elise Dumas (E)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Eric Daoud (E)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Julien Guerin (J)

Data Factory, Institut Curie, Paris, France.

Thomas Balezeau (T)

Data Factory, Institut Curie, Paris, France.

Jean-Guillaume Feron (JG)

Department of Surgery, Institut Curie, University Paris, Paris, France.

Virginie Fourchotte (V)

Department of Surgery, Institut Curie, University Paris, Paris, France.

Youlia Kirova (Y)

Department of Radiation Therapy, Institut Curie, Paris, France.

Florence Lerebours (F)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Jean-Yves Pierga (JY)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Eugénie Guillot (E)

Department of Surgery, Institut Curie, University Paris, Paris, France.

Pietro Santulli (P)

Department of Obstetrics and Gynecology, Hôpital Cochin, University Paris, Paris, France.

Michael Grynberg (M)

Department of Reproductive Medicine and Fertility Preservation, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris Sud, Assistance Publique - Hôpitaux de Paris, Clamart, France.
Department of Reproductive Medicine and Fertility Preservation, Hôpital Jean Verdier, Bondy, France.

Charlotte Sonigo (C)

Department of Reproductive Medicine and Fertility Preservation, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris Sud, Assistance Publique - Hôpitaux de Paris, Clamart, France.

Emmanuel Reyrat (E)

Department of Data and Informatics, Unicancer, Paris, France.

Pauline Soibinet-Oudot (P)

Department of Medical Oncology, Godinot Institute, Reims, France.

Fabien Reyal (F)

Department of Surgery, Institut Curie, University Paris, Paris, France.
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Anne-Sophie Hamy (AS)

Department of Surgery, Institut Curie, University Paris, Paris, France.
Department of Medical Oncology, Institut Curie, University Paris, Paris, France.
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.

Classifications MeSH